145 related articles for article (PubMed ID: 38353798)
61. Pathologic nodal staging scores in patients treated with radical prostatectomy: a postoperative decision tool.
Kluth LA; Abdollah F; Xylinas E; Rieken M; Fajkovic H; Sun M; Karakiewicz PI; Seitz C; Schramek P; Herman MP; Becker A; Loidl W; Pummer K; Nonis A; Lee RK; Lotan Y; Scherr DS; Seiler D; Chun FK; Graefen M; Tewari A; Gönen M; Montorsi F; Shariat SF; Briganti A
Eur Urol; 2014 Sep; 66(3):439-46. PubMed ID: 23850255
[TBL] [Abstract][Full Text] [Related]
62. Time to Disease Recurrence Is a Predictor of Metastasis and Mortality in Patients with High-risk Prostate Cancer Who Achieved Undetectable Prostate-specific Antigen Following Robot-assisted Radical Prostatectomy.
Kim DK; Koo KC; Lee KS; Hah YS; Rha KH; Hong SJ; Chung BH
J Korean Med Sci; 2018 Nov; 33(45):e285. PubMed ID: 30402050
[TBL] [Abstract][Full Text] [Related]
63. Extent of positive surgical margins following radical prostatectomy: impact on biochemical recurrence with long-term follow-up.
Koskas Y; Lannes F; Branger N; Giusiano S; Guibert N; Pignot G; Walz J; Rossi D; Bastide C
BMC Urol; 2019 May; 19(1):37. PubMed ID: 31092240
[TBL] [Abstract][Full Text] [Related]
64. Biochemical recurrence without PSA progression characterizes a subset of patients after radical prostatectomy. Prostate-specific antigen.
Shinghal R; Yemoto C; McNeal JE; Brooks JD
Urology; 2003 Feb; 61(2):380-5. PubMed ID: 12597952
[TBL] [Abstract][Full Text] [Related]
65. When Should a Positive Surgical Margin Ring a Bell? An Analysis of a Multi-Institutional Robot-Assisted Laparoscopic Radical Prostatectomy Database.
Abdollah F; Moschini M; Sood A; Sammon J; Dalela D; Hsu L; Beyer B; Haese A; Graefen M; Gandaglia G; Montorsi F; Briganti A; Menon M
J Endourol; 2016 Feb; 30(2):201-7. PubMed ID: 26415003
[TBL] [Abstract][Full Text] [Related]
66. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
[TBL] [Abstract][Full Text] [Related]
67. Identification of patients at risk for biochemical recurrence after radical prostatectomy with intra-operative frozen section.
Tully KH; Schulmeyer M; Hanske J; Reike MJ; Brock M; Moritz R; Jütte H; Tannapfel A; von Bodman C; Noldus J; Palisaar RJ; Roghmann F
BJU Int; 2021 Nov; 128(5):598-606. PubMed ID: 33961328
[TBL] [Abstract][Full Text] [Related]
68. Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era.
Ung JO; Richie JP; Chen MH; Renshaw AA; D'Amico AV
Urology; 2002 Sep; 60(3):458-63. PubMed ID: 12350484
[TBL] [Abstract][Full Text] [Related]
69. Margin details matter: The prognostic significance of pseudocapsule invasion at the site of involved margin in prostatectomy specimens.
Russo JK; Laszewski M; Rodacker M; Watkins PL; Dufan TA; Koleilat N; Watkins JM
Urol Oncol; 2015 Sep; 33(9):383.e1-7. PubMed ID: 26097050
[TBL] [Abstract][Full Text] [Related]
70. Molecular Lymph Node Status for Prognostic Stratification of Prostate Cancer Patients Undergoing Radical Prostatectomy with Extended Pelvic Lymph Node Dissection.
Heck MM; Retz M; Bandur M; Souchay M; Vitzthum E; Weirich G; Schuster T; Autenrieth M; Kübler H; Maurer T; Thalgott M; Herkommer K; Gschwend JE; Nawroth R
Clin Cancer Res; 2018 May; 24(10):2342-2349. PubMed ID: 29463560
[No Abstract] [Full Text] [Related]
71. Variation in management of lymph node positive prostate cancer after radical prostatectomy within a statewide quality improvement consortium.
Triner D; Daignault-Newton S; Singhal U; Sessine M; Dess RT; Caram MEV; Borza T; Ginsburg KB; Lane BR; Morgan TM;
Urol Oncol; 2024 Jul; 42(7):220.e1-220.e8. PubMed ID: 38570271
[TBL] [Abstract][Full Text] [Related]
72. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
[TBL] [Abstract][Full Text] [Related]
73. Nondissection of pelvic lymph nodes does not influence the results of perineal radical prostatectomy in selected patients.
Salomon L; Hoznek A; Lefrère-Belda MA; Bellot J; Chopin DK; Abbou CC
Eur Urol; 2000 Mar; 37(3):297-300. PubMed ID: 10720855
[TBL] [Abstract][Full Text] [Related]
74. Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the SEARCH database.
Freedland SJ; Aronson WJ; Csathy GS; Kane CJ; Amling CL; Presti JC; Dorey F; Terris MK;
Urology; 2003 Apr; 61(4):742-7. PubMed ID: 12670558
[TBL] [Abstract][Full Text] [Related]
75. External validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer.
Roumiguié M; Beauval JB; Filleron T; Benoit T; Rischmann P; de la Taille A; Salomon L; Soulié M; Malavaud B; Ploussard G
BJU Int; 2014 Dec; 114(6b):E113-E119. PubMed ID: 24684584
[TBL] [Abstract][Full Text] [Related]
76. The impact of the extent of lymph-node dissection on biochemical relapse after radical prostatectomy in node-negative patients.
Schiavina R; Bertaccini A; Franceschelli A; Manferrari F; Vagnoni V; Borghesi M; Morselli-Labate AM; Martorana G
Anticancer Res; 2010 Jun; 30(6):2297-302. PubMed ID: 20651383
[TBL] [Abstract][Full Text] [Related]
77. The number of negative pelvic lymph nodes removed does not affect the risk of biochemical failure after radical prostatectomy.
Murphy AM; Berkman DS; Desai M; Benson MC; McKiernan JM; Badani KK
BJU Int; 2010 Jan; 105(2):176-9. PubMed ID: 19549117
[TBL] [Abstract][Full Text] [Related]
78. Pathological features of lymph node metastasis for predicting biochemical recurrence after radical prostatectomy for prostate cancer.
Carlsson SV; Tafe LJ; Chade DC; Sjoberg DD; Passoni N; Shariat SF; Eastham J; Scardino PT; Fine SW; Touijer KA
J Urol; 2013 Apr; 189(4):1314-8. PubMed ID: 23085057
[TBL] [Abstract][Full Text] [Related]
79. The actual value of the surgical margin status as a predictor of disease progression in men with early prostate cancer.
Vis AN; Schröder FH; van der Kwast TH
Eur Urol; 2006 Aug; 50(2):258-65. PubMed ID: 16413660
[TBL] [Abstract][Full Text] [Related]
80. Therapeutic value of lymph node dissection at radical prostatectomy: a population-based case-cohort study.
Withrow DR; DeGroot JM; Siemens DR; Groome PA
BJU Int; 2011 Jul; 108(2):209-16. PubMed ID: 21044247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
